流式细胞术
CD19
灵敏度(控制系统)
分子生物学
生物
化学
计算生物学
工程类
电子工程
作者
Nicola Schanda,Tim Sauer,Alexander Kunz,Angela Hückelhoven‐Krauss,Brigitte Neuber,Lei Wang,Mandy Hinkelbein,David Sedloev,Bailin He,Maria‐Luisa Schubert,Carsten Müller‐Tidow,Michael Schmitt,Anita Schmitt
出处
期刊:Cells
[Multidisciplinary Digital Publishing Institute]
日期:2021-11-17
卷期号:10 (11): 3208-3208
被引量:20
标识
DOI:10.3390/cells10113208
摘要
Chimeric-antigen-receptor-T (CAR-T) cells are currently revolutionizing the field of cancer immunotherapy. Therefore, there is an urgent need for CAR-T cell monitoring by clinicians to assess cell expansion and persistence in patients. CAR-T cell manufacturers and researchers need to evaluate transduction efficiency and vector copy number for quality control. Here, CAR expression was analyzed in peripheral blood samples from patients and healthy donors by flow cytometry with four commercially available detection reagents and on the gene level by quantitative polymerase chain reaction (qPCR). Flow cytometric analysis of CAR expression showed higher mean CAR expression values for CD19 CAR detection reagent and the F(ab’)2 antibody than Protein L and CD19 Protein. In addition, the CD19 CAR detection reagent showed a significantly lower median background staining of 0.02% (range 0.007–0.06%) when compared to the F(ab’)2 antibody, CD19 protein and Protein L with 0.80% (range 0.47–1.58%), 0.65% (range 0.25–1.35%) and 0.73% (range 0.44–1.23%). Furthermore, flow cytometry-based CAR-T cell frequencies by CD19 CAR detection reagent showed a good correlation with qPCR results. In conclusion, quality control of CAR-T cell products can be performed by FACS and qPCR. For the monitoring of CAR-T cell frequencies by FACS in patients, CAR detection reagents with a low background staining are preferable.
科研通智能强力驱动
Strongly Powered by AbleSci AI